{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:37:53Z","timestamp":1715906273286},"reference-count":52,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Bruton tyrosine kinase (BTK) inhibitors have become a standard of care in the treatment of patients with Waldenstr\u00f6m macroglobulinemia (WM) and are the only medications approved by the FDA to treat these patients. As more patients with WM are treated with BTK inhibitors in the United States and worldwide, it is essential to optimize this therapy by selecting the patients who are more likely to benefit from it, and by managing the unique adverse effects associated with these agents. Herein, we propose a genomic-driven approach to selecting patients with WM who are more likely to experience fast, deep, and durable responses to BTK inhibitors, and provide practical strategies for managing adverse effects, including BTK inhibitor dose reductions, switching to other BTK inhibitors, and abandoning BTK inhibitor therapy. Ongoing clinical trials are evaluating covalent and noncovalent BTK inhibitors alone and in combination, as well as BTK degraders, with exciting results, making the horizon for BTK-targeting therapies in WM bright and hopeful.<\/jats:p>","DOI":"10.6004\/jnccn.2024.7007","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:40:47Z","timestamp":1715863247000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimizing BTK Inhibition in Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.6004","volume":"22","author":[{"given":"Shayna","family":"Sarosiek","sequence":"first","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"N Engl J Med","first-page":"826","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon SP","year":"2012","unstructured":"Treon SP, Xu L, Yang G,  MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 2012;367:826\u2013833."},{"key":"B2","series-title":"Leukemia","first-page":"1722","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"27","author":"Jim\u00e9nez C","year":"2013","unstructured":"Jim\u00e9nez C, Sebasti\u00e1n E, Chill\u00f3n MC,  MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia 2013;27:1722\u20131728."},{"key":"B3","series-title":"Blood","first-page":"4504","article-title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia","volume":"121","author":"Poulain S","year":"2013","unstructured":"Poulain S, Roumier C, Decambron A,  MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121:4504\u20134511."},{"key":"B4","series-title":"Blood","first-page":"1222","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang G","year":"2013","unstructured":"Yang G, Zhou Y, Liu X,  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia. Blood 2013;122:1222\u20131232."},{"key":"B5","series-title":"Blood","first-page":"1637","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter ZR","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G,  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123:1637\u20131646."},{"key":"B6","series-title":"Br J Haematol","first-page":"735","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\u00f6m macroglobulinaemia","volume":"172","author":"Xu L","year":"2016","unstructured":"Xu L, Hunter ZR, Tsakmaklis N,  Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\u00f6m macroglobulinaemia. Br J Haematol 2016;172:735\u2013744."},{"key":"B7","series-title":"Leukemia","first-page":"169","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s macroglobulinemia","volume":"29","author":"Cao Y","year":"2015","unstructured":"Cao Y, Hunter ZR, Liu X,  The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s macroglobulinemia. Leukemia 2015;29:169\u2013176."},{"key":"B8","series-title":"J Clin Oncol","first-page":"88","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani RH","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP,  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 2013;31:88\u201394."},{"key":"B9","series-title":"N Engl J Med","first-page":"1430","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon SP","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K,  Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 2015;372:1430\u20131440."},{"key":"B10","series-title":"J Clin Oncol","first-page":"565","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon SP","year":"2021","unstructured":"Treon SP, Meid K, Gustine J,  Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol 2021;39:565\u2013575."},{"key":"B11","series-title":"J Clin Oncol","first-page":"2755","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon SP","year":"2018","unstructured":"Treon SP, Gustine J, Meid K,  Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol 2018;36:2755\u20132761."},{"key":"B12","series-title":"Leukemia","first-page":"532","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo JJ","year":"2022","unstructured":"Castillo JJ, Meid K, Gustine JN,  Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia 2022;36:532\u2013539."},{"key":"B13","series-title":"N Engl J Med","first-page":"2399","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J,  Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 2018;378:2399\u20132410."},{"key":"B14","series-title":"J Clin Oncol","first-page":"52","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske C","year":"2022","unstructured":"Buske C, Tedeschi A, Trotman J,  Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstr\u00f6m\u2019s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol 2022;40:52\u201362."},{"key":"B15","series-title":"Lancet Oncol","first-page":"241","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos MA","year":"2017","unstructured":"Dimopoulos MA, Trotman J, Tedeschi A,  Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017;18:241\u2013250."},{"key":"B16","series-title":"Clin Cancer Res","first-page":"5793","article-title":"Single-agent ibrutinib for rituximab-refractory Waldenstr\u00f6m macroglobulinemia: final analysis of the substudy of the phase III InnovateTM trial","volume":"27","author":"Trotman J","year":"2021","unstructured":"Trotman J, Buske C, Tedeschi A,  Single-agent ibrutinib for rituximab-refractory Waldenstr\u00f6m macroglobulinemia: final analysis of the substudy of the phase III InnovateTM trial. Clin Cancer Res 2021;27:5793\u20135800."},{"key":"B17","series-title":"Lancet Haematol","first-page":"e112","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen RG","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S,  Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 2020;7:e112\u2013121."},{"key":"B18","series-title":"HemaSphere","first-page":"1020","article-title":"P1130: acalabrutinib in treatment-naive or relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: 5-year follow-up of a phase 2, single-arm study","volume":"6","author":"Owen R","year":"2022","unstructured":"Owen R, McCarthy H, Rule S,  P1130: acalabrutinib in treatment-naive or relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: 5-year follow-up of a phase 2, single-arm study. HemaSphere 2022;6:1020\u20131021."},{"key":"B19","series-title":"Blood","first-page":"2038","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam CS","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S,  A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood 2020;136:2038\u20132050."},{"key":"B20","series-title":"Blood Adv","first-page":"6009","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos M","year":"2020","unstructured":"Dimopoulos M, Sanz RG, Lee HP,  Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv 2020;4:6009\u20136018."},{"key":"B21","series-title":"J Clin Oncol","first-page":"5099","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S,  Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol 2023;41:5099\u20135106."},{"key":"B22","series-title":"Cancer Sci","first-page":"2085","article-title":"Two-year outcomes of tirabrutinib monotherapy in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"113","author":"Sekiguchi N","year":"2022","unstructured":"Sekiguchi N, Rai S, Munakata W,  Two-year outcomes of tirabrutinib monotherapy in Waldenstr\u00f6m\u2019s macroglobulinemia. Cancer Sci 2022;113:2085\u20132096."},{"key":"B23","series-title":"EClinicalMedicine","first-page":"101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao XX","year":"2022","unstructured":"Cao XX, Jin J, Fu CC,  Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine 2022;52:101682."},{"key":"B24","series-title":"Blood","first-page":"2791","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon SP","year":"2014","unstructured":"Treon SP, Cao Y, Xu L,  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014;123:2791\u20132796."},{"key":"B25","series-title":"HemaSphere","first-page":"e624","article-title":"Diagnostic next-generation sequencing frequently fails to detect MYD88L265P in Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Kofides A","year":"2021","unstructured":"Kofides A, Hunter ZR, Xu L,  Diagnostic next-generation sequencing frequently fails to detect MYD88L265P in Waldenstr\u00f6m macroglobulinemia. HemaSphere 2021;5:e624."},{"key":"B26","series-title":"J Clin Oncol","first-page":"5099","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S,  Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol 2023;41:5099\u20135106."},{"key":"B27","series-title":"Haematologica","first-page":"e307","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Castillo JJ","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K,  Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia. Haematologica 2018;103:e307\u2013310."},{"key":"B28","series-title":"Br J Haematol","first-page":"897","article-title":"Dose reductions in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib","volume":"201","author":"Sarosiek S","year":"2023","unstructured":"Sarosiek S, Gustine JN, Flynn CA,  Dose reductions in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib. Br J Haematol 2023;201:897\u2013904."},{"key":"B29","series-title":"Lancet Haematol","first-page":"e35","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman M","year":"2023","unstructured":"Shadman M, Flinn IW, Levy MY,  Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol 2023;10:e35\u201345."},{"key":"B30","series-title":"Am J Hematol","first-page":"511","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine JN","year":"2018","unstructured":"Gustine JN, Meid K, Dubeau T,  Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and IgM rebound. Am J Hematol 2018;93:511\u2013517."},{"key":"B31","series-title":"Br J Haematol","first-page":"98","article-title":"Dexamethasone, rituximab and cyclophosphamide for relapsed and\/or refractory and treatment-na\u00efve patients with Waldenstrom macroglobulinemia","volume":"179","author":"Paludo J","year":"2017","unstructured":"Paludo J, Abeykoon JP, Kumar S,  Dexamethasone, rituximab and cyclophosphamide for relapsed and\/or refractory and treatment-na\u00efve patients with Waldenstrom macroglobulinemia. Br J Haematol 2017;179:98\u2013105."},{"key":"B32","series-title":"Ann Hematol","first-page":"1417","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo J","year":"2018","unstructured":"Paludo J, Abeykoon JP, Shreders A,  Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia. Ann Hematol 2018;97:1417\u20131425."},{"key":"B33","series-title":"Leuk Lymphoma","first-page":"2637","article-title":"Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstr\u00f6m macroglobulinemia","volume":"56","author":"Tedeschi A","year":"2015","unstructured":"Tedeschi A, Picardi P, Ferrero S,  Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstr\u00f6m macroglobulinemia. Leuk Lymphoma 2015;56:2637\u20132642."},{"key":"B34","series-title":"J Clin Oncol","first-page":"1422","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial IM","year":"2010","unstructured":"Ghobrial IM, Hong F, Padmanabhan S,  Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422\u20131428."},{"key":"B35","series-title":"Blood","first-page":"344","article-title":"Ixazomib, rituximab and dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom\u2019s macroblobulinemia: results of the prospective phase I\/II HOVON 124\/Ecwm-R2 trial","volume":"134","author":"Kersten MJ","year":"2019","unstructured":"Kersten MJ, Minnema MC, Vos JM,  Ixazomib, rituximab and dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom\u2019s macroblobulinemia: results of the prospective phase I\/II HOVON 124\/Ecwm-R2 trial. Blood 2019;134(Suppl 1):344."},{"key":"B36","series-title":"Clin Cancer Res","first-page":"3320","article-title":"Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom\u2019s macroglobulinemia: results of WMCTG Trial 03-248","volume":"13","author":"Treon SP","year":"2007","unstructured":"Treon SP, Hunter ZR, Matous J,  Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom\u2019s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320\u20133325."},{"key":"B37","series-title":"Blood","first-page":"503","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"124","author":"Treon SP","year":"2014","unstructured":"Treon SP, Tripsas CK, Meid K,  Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia. Blood 2014;124:503\u2013510."},{"key":"B38","series-title":"Am J Hematol","first-page":"E95","article-title":"CXCR4 mutational status does not impact outcomes in patients with Waldenstr\u00f6m macroglobulinemia treated with proteasome inhibitors","volume":"95","author":"Castillo JJ","year":"2020","unstructured":"Castillo JJ, Gustine JN, Meid K,  CXCR4 mutational status does not impact outcomes in patients with Waldenstr\u00f6m macroglobulinemia treated with proteasome inhibitors. Am J Hematol 2020;95:E95\u201398."},{"key":"B39","series-title":"Clin Cancer Res","first-page":"3247","article-title":"Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstr\u00f6m macroglobulinemia","volume":"24","author":"Castillo JJ","year":"2018","unstructured":"Castillo JJ, Meid K, Gustine JN,  Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstr\u00f6m macroglobulinemia. Clin Cancer Res 2018;24:3247\u20133252."},{"key":"B40","series-title":"Blood","first-page":"2608","article-title":"Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients","volume":"132","author":"Sklavenitis-Pistofidis R","year":"2018","unstructured":"Sklavenitis-Pistofidis R, Capelletti M, Liu CJ,  Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood 2018;132:2608\u20132612."},{"key":"B41","series-title":"J Clin Oncol","first-page":"63","article-title":"Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"40","author":"Castillo JJ","year":"2022","unstructured":"Castillo JJ, Allan JN, Siddiqi T,  Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia. J Clin Oncol 2022;40:63\u201371."},{"key":"B42","series-title":"Blood","first-page":"2047","article-title":"BTKCys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen JG","year":"2018","unstructured":"Chen JG, Liu X, Munshi M,  BTKCys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood 2018;131:2047\u20132059."},{"key":"B43","series-title":"Blood Cancer J","first-page":"e565","article-title":"Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment","volume":"7","author":"Paulus A","year":"2017","unstructured":"Paulus A, Akhtar S, Yousaf H,  Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 2017;7:e565."},{"key":"B44","series-title":"Lancet","first-page":"892","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato AR","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W,  Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 2021;397:892\u2013901."},{"key":"B45","series-title":"Blood","first-page":"557","article-title":"Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study","volume":"140","author":"Palomba ML","year":"2022","unstructured":"Palomba ML, Patel MR, Eyre TA,  Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed\/refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study. Blood 2022;140(Suppl 1):557\u2013560."},{"key":"B46","series-title":"Cancer Discov","first-page":"1300","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff SD","year":"2018","unstructured":"Reiff SD, Mantel R, Smith LL,  The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation. Cancer Discov 2018;8:1300\u20131315."},{"key":"B47","series-title":"Blood","first-page":"392","article-title":"Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study","volume":"138","author":"Woyach JA","year":"2021","unstructured":"Woyach JA, Flinn IW, Awan FT,  Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study. Blood 2021;138(Suppl 1):392."},{"key":"B48","series-title":"N Engl J Med","first-page":"735","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang E","year":"2022","unstructured":"Wang E, Mi X, Thompson MC,  Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med 2022;386:735\u2013743."},{"key":"B49","series-title":"Cancer Res","first-page":"2850","article-title":"NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants","volume":"83","author":"Noviski MA","year":"2023","unstructured":"Noviski MA, Brathaban N, Mukerji R,  NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants. Cancer Res 2023;83(7_Suppl):2850."},{"key":"B50","series-title":"Blood","first-page":"2251","article-title":"Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies","volume":"138","author":"Robbins DW","year":"2021","unstructured":"Robbins DW, Noviski M, Rountree R,  Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies. Blood 2021;138(Suppl 1):2251."},{"key":"B51","series-title":"Br J Haematol","first-page":"709","article-title":"Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study","volume":"172","author":"Castillo JJ","year":"2016","unstructured":"Castillo JJ, D\u2019Sa S, Lunn MP,  Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol 2016;172:709\u2013715."},{"key":"B52","series-title":"Blood","first-page":"140","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato AR","year":"2022","unstructured":"Mato AR, Wierda WG, Ai WZ,  NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies. Blood 2022;140(Suppl 1):140."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/4\/article-e247007.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/4\/article-e247007.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/4\/article-e247007.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:40:47Z","timestamp":1715863247000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/4\/article-e247007.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":52,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7007","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}